| Literature DB >> 27151442 |
Vaishali Kakkar1, Cecilia Månsson2, Eduardo P de Mattos3, Steven Bergink1, Marianne van der Zwaag1, Maria A W H van Waarde1, Niels J Kloosterhuis4, Ronald Melki5, Remco T P van Cruchten2, Salam Al-Karadaghi2, Paolo Arosio6, Christopher M Dobson6, Tuomas P J Knowles6, Gillian P Bates7, Jan M van Deursen8, Sara Linse2, Bart van de Sluis4, Cecilia Emanuelsson2, Harm H Kampinga9.
Abstract
Expanded CAG repeats lead to debilitating neurodegenerative disorders characterized by aggregation of proteins with expanded polyglutamine (polyQ) tracts. The mechanism of aggregation involves primary and secondary nucleation steps. We show how a noncanonical member of the DNAJ-chaperone family, DNAJB6, inhibits the conversion of soluble polyQ peptides into amyloid fibrils, in particular by suppressing primary nucleation. This inhibition is mediated by a serine/threonine-rich region that provides an array of surface-exposed hydroxyl groups that bind to polyQ peptides and may disrupt the formation of the H bonds essential for the stability of amyloid fibrils. Early prevention of polyQ aggregation by DNAJB6 occurs also in cells and leads to delayed neurite retraction even before aggregates are visible. In a mouse model, brain-specific coexpression of DNAJB6 delays polyQ aggregation, relieves symptoms, and prolongs lifespan, pointing to DNAJB6 as a potential target for disease therapy and tool for unraveling early events in the onset of polyQ diseases.Entities:
Year: 2016 PMID: 27151442 DOI: 10.1016/j.molcel.2016.03.017
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970